Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1990 1
1991 1
2002 1
2004 1
2010 1
2011 1
2013 1
2016 3
2018 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.
Wang X, Wang S, Yao S, Shi W, Ma K. Wang X, et al. J Ovarian Res. 2022 Sep 16;15(1):104. doi: 10.1186/s13048-022-01037-6. J Ovarian Res. 2022. PMID: 36114551 Free PMC article. Review.
BACKGROUND: Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. ...Heterologous sarcoma component did not shorten life expectancy. The optimal ovarian tumor cell debulking surgery (OOTCDS), radiotherapy and chemotherapy could sign …
BACKGROUND: Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. ...Heterologous sarcoma component did no …
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A. Friedlander ML, et al. Int J Gynecol Cancer. 2016 May;26(4):648-54. doi: 10.1097/IGC.0000000000000677. Int J Gynecol Cancer. 2016. PMID: 26937756 Free PMC article.
BACKGROUND: Advanced stage/recurrent clear cell ovarian cancers (CCOCs) are characterized by a low response to chemotherapy and a poor prognosis. ...CONCLUSIONS: This large study confirms that the PIK3CA/Akt/mTOR pathway is commonly altered in CCOCs, and highlights …
BACKGROUND: Advanced stage/recurrent clear cell ovarian cancers (CCOCs) are characterized by a low response to chemotherapy an …
Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome.
Garrett LA, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG. Garrett LA, et al. J Reprod Med. 2013 Nov-Dec;58(11-12):469-76. J Reprod Med. 2013. PMID: 24568040
OBJECTIVE: To investigate the relationship of age and tumors associated with endometriosis and outcome of different histologies of epithelial ovarian cancer arising from endometriosis. STUDY DESIGN: We identified cases of epithelial ovarian cancers with clear cel …
OBJECTIVE: To investigate the relationship of age and tumors associated with endometriosis and outcome of different histologies of epithelia …
Analgesic use and risk of renal cell carcinoma: A case-control, cohort and meta-analytic assessment.
Karami S, Daughtery SE, Schwartz K, Davis FG, Ruterbusch JJ, Wacholder S, Graubard BI, Berndt SI, Hofmann JN, Purdue MP, Moore LE, Colt JS. Karami S, et al. Int J Cancer. 2016 Aug 1;139(3):584-92. doi: 10.1002/ijc.30108. Epub 2016 Apr 9. Int J Cancer. 2016. PMID: 27009534 Free PMC article.
Evidence that analgesics increase kidney cancer risk has been mixed. We investigated the association between renal cell carcinoma (RCC) and analgesic use in a large population-based case-control study and a post-trial observational cohort study. ...We analyzed data …
Evidence that analgesics increase kidney cancer risk has been mixed. We investigated the association between renal cell carcin …
Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Shappell HW, et al. Am J Surg Pathol. 2002 Dec;26(12):1529-41. doi: 10.1097/00000478-200212000-00001. Am J Surg Pathol. 2002. PMID: 12459620 Review.
In addition, they all contained endometrioid-type cells, hobnail cells, and indifferent cells with abundant eosinophilic cytoplasm to a varying degree. Accordingly, it appears that tumors that feature endocervical-type mucinous cells are rarely if ever …
In addition, they all contained endometrioid-type cells, hobnail cells, and indifferent cells with abundant eosinophili …
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach.
Hayes-Jordan A, Lopez C, Green HL, Xiao LC, Huh W, Herzog CE. Hayes-Jordan A, et al. Pediatr Surg Int. 2016 Jan;32(1):71-3. doi: 10.1007/s00383-015-3814-9. Pediatr Surg Int. 2016. PMID: 26500075 Free PMC article.
Patients with disease outside of the abdominal cavity were excluded. RESULTS: Of 101 pediatric CRS and HIPEC operations, 8 had ovarian primary tumors and multifocal peritoneal disease. There were three yolk sac tumors (germ cell, mixed teratoma), one Sertoli- …
Patients with disease outside of the abdominal cavity were excluded. RESULTS: Of 101 pediatric CRS and HIPEC operations, 8 had ovarian …
Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects.
Altaras MM, Aviram R, Cohen I, Cordoba M, Weiss E, Beyth Y. Altaras MM, et al. Gynecol Oncol. 1991 Mar;40(3):230-6. doi: 10.1016/0090-8258(90)90283-q. Gynecol Oncol. 1991. PMID: 2013445
Tumor histology revealed papillary serous carcinoma in six and mixed (papillary serous and papillary clear cell carcinoma) in one patient. ...To the best of our knowledge, the usefulness of CA-125 in the diagnosis, management, follow-up, and determination of tumor s …
Tumor histology revealed papillary serous carcinoma in six and mixed (papillary serous and papillary clear cell carcinoma) in …
Role of HNF1beta in the differential diagnosis of yolk sac tumor from other germ cell tumors.
Rougemont AL, Tille JC. Rougemont AL, et al. Hum Pathol. 2018 Nov;81:26-36. doi: 10.1016/j.humpath.2018.04.025. Epub 2018 May 16. Hum Pathol. 2018. PMID: 29753846
Identification of the yolk sac tumor (YST) component in germ cell tumors (GCT) may prove challenging, and highly sensitive and specific immunohistochemical markers are still lacking. ...A cohort of 49 YST specimens from 45 patients was designed, occurring either as pure tu …
Identification of the yolk sac tumor (YST) component in germ cell tumors (GCT) may prove challenging, and highly sensitive and specif …
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK. Kim YM, et al. J Gynecol Oncol. 2019 May;30(3):e32. doi: 10.3802/jgo.2019.30.e32. J Gynecol Oncol. 2019. PMID: 30887755 Free PMC article.
OBJECTIVE: Somatic TP53 mutation (TP53(mut)) is a characteristic finding in high-grade serous ovarian cancer (HGSOC). The aim of this study was to assess the clinical efficacy and utility of TP53(mut) circulating tumor DNA (ctDNA) monitoring as a biomarker for managing HGS …
OBJECTIVE: Somatic TP53 mutation (TP53(mut)) is a characteristic finding in high-grade serous ovarian cancer (HGSOC). The aim of this …
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S. Magazzino F, et al. Int J Gynecol Cancer. 2011 Aug;21(6):1063-70. doi: 10.1097/IGC.0b013e318218f270. Int J Gynecol Cancer. 2011. PMID: 21633300
OBJECTIVE: Clear cell ovarian carcinoma has a poorer prognosis compared with other histological subtypes. ...In 62.9%, clear cell histology was pure, whereas in the other cases, a mixed population was evident. ...
OBJECTIVE: Clear cell ovarian carcinoma has a poorer prognosis compared with other histological subtypes. ...In 62.9%, clear …
14 results